Covance Stock Price, News & Analysis (NYSE:CVD)

$107.07 0.00 (0.00 %)
(As of 12/18/2017 01:49 AM ET)
Previous Close$107.07
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market Capitalization$6.06 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Covance (NYSE:CVD)

Covance logoCovance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.

Receive CVD News and Ratings via Email

Sign-up to receive the latest news and ratings for CVD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryLife Sciences Tools & Services
SectorHealthcare
SymbolNYSE:CVD
CUSIP22281610
Phone+1-609-4524440

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS$3.24
Net IncomeN/A
Net Margins7.70%
Return on Equity12.64%
Return on Assets8.17%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Covance (NYSE:CVD) Frequently Asked Questions

What is Covance's stock symbol?

Covance trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVD."

How were Covance's earnings last quarter?

Covance Inc. (NYSE:CVD) released its quarterly earnings data on Wednesday, February, 4th. The healthcare company reported $0.97 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.97. The healthcare company had revenue of $634 million for the quarter, compared to analyst estimates of $631.30 million. Covance had a net margin of 7.70% and a return on equity of 12.64%. View Covance's Earnings History.

Who are some of Covance's key competitors?

How do I buy Covance stock?

Shares of Covance can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Covance's stock price today?

One share of Covance stock can currently be purchased for approximately $107.07.

How big of a company is Covance?

Covance has a market capitalization of $6.06 billion.

How can I contact Covance?

Covance's mailing address is 210 Carnegie Ctr, PRINCETON, NJ 08540-6233, United States. The healthcare company can be reached via phone at +1-609-4524440.


MarketBeat Community Rating for Covance (CVD)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  289
MarketBeat's community ratings are surveys of what our community members think about Covance and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Covance (NYSE:CVD) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Covance (NYSE:CVD) Earnings History and Estimates Chart

Earnings by Quarter for Covance (NYSE:CVD)

Covance (NYSE CVD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/4/2015Q414$0.97$0.97$631.30 million$634.00 millionViewN/AView Earnings Details
11/3/2014Q314$0.98$0.98$651.00 million$627.00 millionViewN/AView Earnings Details
7/29/2014Q214$0.93$0.95$639.80 million$687.10 millionViewN/AView Earnings Details
5/1/2014Q114$0.90$0.90$632.01 million$620.10 millionViewN/AView Earnings Details
2/4/2014Q413$0.84$0.87$613.80 million$623.00 millionViewN/AView Earnings Details
7/30/2013Q2 2013$0.77$0.78$586.12 million$644.00 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.72$0.75$569.34 million$580.20 millionViewN/AView Earnings Details
1/24/2013Q4 2012$0.71$0.73$548.84 million$562.20 millionViewN/AView Earnings Details
11/5/2012Q312$0.67$0.72$546.52 million$597.66 millionViewN/AView Earnings Details
7/25/2012$0.64$0.65ViewN/AView Earnings Details
5/2/2012$0.60$0.68ViewN/AView Earnings Details
1/25/2012$0.73$0.73ViewN/AView Earnings Details
11/2/2011$0.70$0.71ViewN/AView Earnings Details
7/27/2011$0.65$0.66ViewN/AView Earnings Details
5/5/2011$0.58$0.60ViewN/AView Earnings Details
1/26/2011$0.53$0.56ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Covance (NYSE:CVD) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Covance (NYSE:CVD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Covance (NYSE CVD) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Covance (NYSE:CVD)

Covance (NYSE CVD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/22/2014Brian H NuttInsiderSell1,127$103.51$116,655.77View SEC Filing  
12/18/2014Joseph L HerringCEOSell32,692$103.02$3,367,929.84View SEC Filing  
12/10/2014John E WatsonVPSell15,200$102.94$1,564,688.00View SEC Filing  
9/9/2014Joseph L HerringCEOSell32,200$85.13$2,741,186.00View SEC Filing  
2/20/2014James LovettVPSell14,955$102.47$1,532,438.85View SEC Filing  
2/10/2014Brian NuttInsiderSell1,808$100.12$181,016.96View SEC Filing  
2/10/2014Richard CiminoEVPSell13,000$99.10$1,288,300.00View SEC Filing  
2/10/2014Sandra HeltonDirectorSell2,800$99.03$277,284.00View SEC Filing  
9/20/2013Richard CiminoEVPSell16,000$84.86$1,357,760.00View SEC Filing  
9/5/2013Sandra L HeltonDirectorSell3,000$81.92$245,760.00View SEC Filing  
9/5/2013William E KlitgaardVPSell25,323$81.44$2,062,305.12View SEC Filing  
8/21/2013Deborah KellerEVPSell15,900$83.12$1,321,608.00View SEC Filing  
8/16/2013Robert BarchiDirectorSell13,667$82.78$1,131,354.26View SEC Filing  
8/2/2013Gary CostleyDirectorSell7,467$82.77$618,043.59View SEC Filing  
8/2/2013Joseph HerringCEOSell100,000$82.54$8,254,000.00View SEC Filing  
6/27/2013Joseph L HerringCEOSell13,259$77.00$1,020,943.00View SEC Filing  
6/19/2013Joseph L HerringCEOSell22,391$78.03$1,747,169.73View SEC Filing  
5/15/2013James W LovettVPSell10,259$77.00$789,943.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Covance (NYSE CVD) News Headlines

Source:
DateHeadline
Bio-Techne (TECH) and Covance (CVD) Head to Head ContrastBio-Techne (TECH) and Covance (CVD) Head to Head Contrast
www.americanbankingnews.com - December 10 at 7:54 AM
Head to Head Survey: Alnylam Pharmaceuticals (ALNY) and Covance (CVD)Head to Head Survey: Alnylam Pharmaceuticals (ALNY) and Covance (CVD)
www.americanbankingnews.com - November 27 at 1:36 AM
Reviewing Codexis (CDXS) and Covance (CVD)Reviewing Codexis (CDXS) and Covance (CVD)
www.americanbankingnews.com - October 14 at 4:14 AM
Reviewing Covance (NYSE:CVD) and Regulus Therapeutics (RGLS)Reviewing Covance (NYSE:CVD) and Regulus Therapeutics (RGLS)
www.americanbankingnews.com - August 4 at 10:16 PM
LabCorp extends process improvement initiative to Covance, $30M charge planned to cover costs associated with job cuts and facility closures; shares slip 4%LabCorp extends process improvement initiative to Covance, $30M charge planned to cover costs associated with job cuts and facility closures; shares slip 4%
seekingalpha.com - April 25 at 3:58 PM
INC Research Holdings Seen as Likely LabCorp. Takeover TargetINC Research Holdings Seen as Likely LabCorp. Takeover Target
us.rd.yahoo.com - December 12 at 12:12 PM
INC Research: Strong quarter boosts bull thesis, bodes well for pharma services peersINC Research: Strong quarter boosts bull thesis, bodes well for pharma services peers
seekingalpha.com - October 31 at 10:28 AM
Covance Receives Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award Three Years RunningCovance Receives Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award Three Years Running
au.finance.yahoo.com - October 12 at 9:49 PM
INC Research Holdings In The Spotlight As Rumors Of A Suitor CirculateINC Research Holdings In The Spotlight As Rumors Of A Suitor Circulate
seekingalpha.com - May 3 at 7:14 AM
Testing LabCorps Deal PlansTesting LabCorp's Deal Plans
www.bloomberg.com - April 19 at 11:00 AM
LabCorps King: 2015 was transformativeLabCorp's King: 2015 was 'transformative'
www.bizjournals.com - February 18 at 1:00 PM
Laboratory Corp. of America (LH) Stock Gains on Earnings BeatLaboratory Corp. of America (LH) Stock Gains on Earnings Beat
www.thestreet.com - October 26 at 3:57 PM
Covance deal continues to fuel revenue, earnings growth for LabCorpCovance deal continues to fuel revenue, earnings growth for LabCorp
www.bizjournals.com - October 26 at 2:00 PM
[$$] LabCorps Sales Soars Following Covance Buy[$$] LabCorp's Sales Soars Following Covance Buy
www.wsj.com - October 26 at 7:51 AM
LabCorp expands beyond labwork with purchase of food and beverage companyLabCorp expands beyond labwork with purchase of food and beverage company
www.bizjournals.com - October 23 at 2:20 PM
Laboratory Corp Of America (LH) Earnings Report: Q2 2015 Conference Call TranscriptLaboratory Corp Of America (LH) Earnings Report: Q2 2015 Conference Call Transcript
www.thestreet.com - July 28 at 5:39 PM

SEC Filings

Covance (NYSE:CVD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Covance (NYSE:CVD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Covance (NYSE CVD) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.